August
AboutAccuMedicalAboutAccuMedical
AccuMedical Inc. is a pioneering medical device company dedicated to advancing neurointerventional care. With a vertically integrated system spanning R&D, precision manufacturing, and global operations, we provide end-to-end solutions covering hemorrhagic stroke, ischemic stroke, and vascular access.AccuMedical Inc. is a pioneering medical device company dedicated to advancing neurointerventional care. With a vertically integrated system spanning R&D, precision manufacturing, and global operations, we provide end-to-end solutions covering hemorrhagic stroke, ischemic stroke, and vascular access.
By leveraging dual R&D centers in the United States and China, we bridge engineering excellence with clinical practice to address complex clinical challenges. Our strategic commercial hub in Singapore anchors our global operations, ensuring agile response and dedicated support for international markets.By leveraging dual R&D centers in the United States and China, we bridge engineering excellence with clinical practice to address complex clinical challenges. Our strategic commercial hub in Singapore anchors our global operations, ensuring agile response and dedicated support for international markets.
Treat, as our own
Our Mission
Accuracy Touches Lives
Our Mission
Accuracy Honors Virtus
Our Mission
Accuracy Builds Fides
In neurointervention, every precise movement carries the weight of a life. Accuracy is more than technical precision. It is a promise to patients, a profound respect for physicians, and the foundation of lasting partnerships.
This is what drives us: to deliver Accuracy that Touches Lives, Honors Virtus, and Builds Fides.
Our Story
2017
2020
May
Lattice approved for the Special Review Process for Innovative Medical Devices (Green Channel) by the National Medical Products Administration (NMPA).
2021
January
AccuMedical was designated as a "Specialized and Sophisticated SMEs" by the Beijing Municipal Economic and Information Bureau.
November
AccuMedical obtained certification for the enterprise intellectual property management system and the production of medical devices (license).
November
Completion of pre-market clinical trial, LIFE (Lattice Intracranial Flow Diverter Evaluation of Clinical Use).
2022
February
cosine71/58 Distal Access Catheter approved for marketing by NMPA.
June
sine approved for marketing by NMPA.
August
AccuMedical was included in the "Beijing Intellectual Property Pilot Enterprise" by the Beijing Intellectual Property Bureau.
October
Lattice approved for marketing by NMPA.
2023
June
sine 21 Microcatheter approved for marketing by NMPA.
July
cosine 45 Distal Access Catheter approved for marketing by NMPA.
October
attractor Aspiration Catheter approved for marketing by NMPA.
December
AccuMedical was designated as a National High-Tech Enterprise.
December
Lattice Flow Diverter and cosine Distal Access Catheter were certified as Beijing New Technology & Product.
2024
January
cosine Distal Access Catheter approved for marketing by FDA.
April
Paracurve Radial Access Guiding Catheter approved for marketing by NMPA.
July
AccuMedical was designated as a National-level "Little Giant" Enterprise.
October
Lattice NEXT Flow Diverter approved for marketing by NMPA.
December
Lattice Flow Diverter was supported by the “First Market Entry of New Technology and Product program”.
December
AccuMedical was designated as a Beijing Enterprise Technology Center.
2025
March
Lattice COUPLE approved for marketing by NMPA.
August
grism Stent Retriever approved for marketing by NMPA.
November
AccuMedical selected as a "Beijing Intellectual Property Advantage Enterprise" by the Beijing Intellectual Property Bureau.
2026
February
AccuMedical selected as a Candidate for National Intellectual Property Demonstration Enterprise.
June
Lattice Flow Diverter approved for marketing by EU MDR CE.
June
grism Stent Retriever approved for marketing by EU MDR CE.
Brand Values
Unmet clinical needs drive our innovation. Operating from dual R&D centers in Beijing and California, our multidisciplinary team translates real-world clinical insights into cutting-edge neurointerventional technologies. Having mastered core proprietary technologies and secured over 100 patents worldwide, we continuously push the boundaries of cerebrovascular care.
